Vaccine breakthrough stops cancer returning in trial
Pre-surgery immunotherapy has kept a group of bowel cancer patients cancer-free for nearly three years. The trial utilized personalized blood tests to help predict how patients would respond to the treatment. This success in bowel cancer treatment arrives as other mRNA-based efforts face mixed results, including a mid-stage study termination by BioNTech and ongoing FDA approval efforts from Moderna for a melanoma vaccine.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Pre-surgery immunotherapy kept a group of bowel cancer patients cancer-free for nearly three years.
- ✓ Personalized blood tests were used to predict treatment response in the bowel cancer trial.
What changed
A bowel cancer trial demonstrated that pre-surgery immunotherapy prevented cancer return for nearly three years.
Live updates
-
Immunotherapy Trial Keeps Bowel Cancer Patients Cancer-Free for Nearly Three Years
Pre-surgery immunotherapy has kept a group of bowel cancer patients cancer-free for nearly three years. The trial utilized personalized blood tests to help predict how patients would respond to the treatment. This success in bowel cancer treatment arrives as other mRNA-based efforts face mixed results, including a mid-stage study termination by BioNTech and ongoing FDA approval efforts from Moderna for a melanoma vaccine.
Why it matters
Cancer vaccines and immunotherapies aim to prevent recurrence by training the immune system to target malignant cells. While AI is expected to accelerate these cures, chip shortages have hindered the development of AI-driven treatments. Success in bowel cancer trials provides a potential roadmap for personalized oncology.
What is confirmed
- Pre-surgery immunotherapy kept a group of bowel cancer patients cancer-free for nearly three years.
- Personalized blood tests were used to predict treatment response in the bowel cancer trial.
What to watch next
- FDA decision on Moderna's mRNA melanoma vaccine
- Peer-reviewed publication of the bowel cancer immunotherapy trial data
confidence 100%Sources used for this update (13)
- jen.jiji.com — Women's World Cup, Italy almost pulls off the feat, eliminated 82-80 by Australia
- jen.jiji.com — Fenerbahce-Roma, Gasperini demands three penalties: what happened in Champions
- jen.jiji.com — Bad weather, one dead in the Siena area. A woman drowns in a car in Udine
- scitechdaily.com — “Cancer Melted Away”: Immunotherapy Delivers Striking Results in Bowel Cancer Trial
- jen.jiji.com — US Open, today Shelton-Tiafoe: time, head-to-head, and where to watch it on TV
- jen.jiji.com — World Sepsis Day, Zerocalcare-anesthetists 'recognizing it immediately can save a life'
- jen.jiji.com — France, train derails on Rouen-Caen line: 20 injured
- jen.jiji.com — Ultimate Championship, it's Jacobs' turn: the Azzurri competing today in the 'World of Worlds' and where to watch them
- jen.jiji.com — Serie A, today Lazio-Milan - Live
- scitechdaily.com — Scientists Used Cancer Therapy To Reset Rheumatoid Arthritis
- jen.jiji.com — Mattarella on AI: "States must regain lost sovereignty over private entities"
- jen.jiji.com — Trump against Supreme Court, 'bullied by extreme left, worst decisions in history'
-
BioNTech Halts mRNA Cancer Trial Amid Moderna FDA Bid
BioNTech SE is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee found that continuing was unlikely to show effectiveness. This setback for BioNTech contrasts with Moderna, which is seeking FDA approval for its own mRNA melanoma vaccine used with Keytruda following positive Phase 3 results. While AI is viewed as a tool for future cures, some industry leaders warn that chip shortages are currently slowing the development of AI-driven cancer treatments.
Why it matters
Personalized mRNA vaccines aim to prevent cancer from returning by tailoring treatments to a patient's specific tumor. Moderna's success in melanoma trials led to a 177% stock increase by August 19, 2026. The industry is now split between successful clinical progressions and failures in mid-stage efficacy.
What is confirmed
- BioNTech SE is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran.
- Moderna is pursuing FDA approval for a personalized mRNA vaccine to prevent melanoma from returning or spreading.
Still unconfirmed
- Artificial intelligence will find a cure for cancer that humans cannot in their lifetimes.
What to watch next
- FDA decision on Moderna's melanoma vaccine application
- Further data on the survival imbalance identified in the BioNTech trial
confidence 90%Sources used for this update (6)
- finance.yahoo.com — BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?
- www.myjoyonline.com — AI cancer cures slowed by chip shortage, says UK’s biggest tech boss
- www.yahoo.com — AI is unlocking a new ‘golden age’ in medicine, with personalized treatments to cure cancer and potential to save billions of lives
- jen.jiji.com — Pensions, Fornero: "Giorgetti contradicts himself, the League's proposal also creates unequal treatment"
- jen.jiji.com — Former Ilva, layoffs suspended until ruling: government open to public participation
- pressofatlanticcity.com — NASA's newest Mars images offer striking clues to Earth's neighbor
-
Moderna Seeks FDA Approval for Personalized mRNA Melanoma Vaccine
Moderna is pursuing FDA approval for a personalized mRNA vaccine designed to prevent melanoma from returning or spreading in high-risk patients. The vaccine is administered in combination with the drug Keytruda. Phase 3 clinical trials have concluded, and CEO Stephane Bancel indicated that the company will continue to refine the algorithm used to develop the treatment. The positive trial outcomes contributed to a 177% increase in Moderna stock as of August 19, 2026.
Why it matters
mRNA technology allows for vaccines tailored to the specific genetic mutations of a patient's tumor. This approach aims to prime the immune system to recognize and attack remaining cancer cells. Successful approval would mark a shift toward personalized oncology treatments.
What is confirmed
- Moderna is seeking FDA approval for a personalized mRNA vaccine targeting melanoma.
- The vaccine is used alongside the drug Keytruda to prevent cancer recurrence or spread in high-risk patients.
- Moderna stock rose 177% as of August 19, 2026, following trial results.
- CEO Stephane Bancel stated the algorithm for the vaccine will continue to improve.
What to watch next
- FDA decision on the vaccine application
- Publication of detailed phase 3 clinical trial data
- Expansion of the mRNA algorithm to other cancer types
confidence 100%Sources used for this update (8)
- jen.jiji.com — The 'kangaroo move' to evade speed cameras, this is how they avoid fines
- www.myjoyonline.com — Breast Cancer survivor Miriam Ablah Anani breaks silence on infertility stigma, abandonment and cancer battle
- www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
- jen.jiji.com — Ukraine-Russia, Zelensky welcomes Trump's envoys in Kyiv - Video
- www.dailymail.com — It's the attention disorder affecting 2.5million Britons and a host of celebrities - but now experts warn ADHD's restlessness, trouble concentrating and memory problem…
- jen.jiji.com — Germany, AfD landslide in Saxony-Anhalt elections: "We made history"
- www.myjoyonline.com — Ghanaian vaccine makers gain access to 1.4bn African market under new deal
- www.myjoyonline.com — Kwamigah-Atokple backs cancer research centre proposal for UHAS
-
Moderna CEO Says Cancer Vaccine Algorithm Will Improve After Trial Success
Moderna CEO Stephane Bancel stated that the algorithm used for the company's successful cancer vaccine will continue to improve. This follows the completion of phase 3 clinical trials for a personalized mRNA vaccine targeting melanoma, which was administered alongside the drug Keytruda to prevent cancer from returning or spreading in high-risk patients. The trial results have already caused Moderna stock to rise 177% as of August 19, 2026, and the company is now positioned to seek FDA approval.
Why it matters
The breakthrough comes after 20 years of research and over a thousand failed trials. This personalized approach aims to reduce recurrence rates in melanoma patients. The financial markets have reacted strongly to the milestone, impacting both Moderna and five associated biotechnology manufacturing firms.
What is confirmed
- Moderna and Merck completed phase 3 clinical trials for a personalized mRNA melanoma vaccine used with Keytruda.
- Moderna stock increased 177% on August 19, 2026.
Still unconfirmed
- The cancer vaccine development involved more than a thousand failed trials over 20 years.
- The algorithm behind the cancer vaccine will continue to get better.
What to watch next
- FDA approval decision for the personalized mRNA vaccine
- Further updates on the vaccine algorithm's performance in subsequent trials
confidence 90%Sources used for this update (12)
- jen.jiji.com — W.Post, Pentagon hires military influencers close to Hegseth for civilian roles
- jen.jiji.com — Serie A, today Atalanta-Bologna: time, probable lineups and where to watch it on TV
- jen.jiji.com — US Open, third day: from Musetti to Cobolli, schedule and where to watch them on TV
- jen.jiji.com — Flood in Nepal and Tibet, over 1,000 dead
- jen.jiji.com — Boiling Mediterranean, July 2026 was the hottest July since 1993
- jen.jiji.com — Luigi Berlusconi has become a father for the third time, Miriam Rosa is born
- jen.jiji.com — Monza GP, Hamilton and Leclerc's promise: "Here to win"
- finance.biggo.com — Moderna CEO Stéphane Bancel: The Algorithm Behind Our Cancer Vaccine Will Only Get Better
- www.dailymail.com — Virus lying dormant in 90% of people can 'reactivate' and cause major brain, nerve and organ damage
- jen.jiji.com — US Open, Sabalenka complains about a spectator: "He's smoking marijuana"
- jen.jiji.com — Earthquake today in Cosenza, magnitude 3.7 tremor: felt throughout the province
- www.statnews.com — The paperwork was never really the problem with clozapine
-
Moderna and Merck mRNA Cancer Vaccine Meets Phase 3 Trial Goals
Moderna and Merck have successfully completed phase 3 clinical trials for a personalized mRNA vaccine targeting melanoma. The treatment, used in combination with the drug Keytruda, aims to prevent the cancer from returning or spreading in high-risk patients. This achievement marks the final milestone needed for the companies to seek FDA approval. The trial results have already impacted the financial markets, with Moderna stock increasing 177% on August 19, 2026. Five biotechnology firms involved in the manufacturing process have also seen their stock prices fluctuate due to these developments.
Why it matters
Personalized mRNA vaccines represent a shift toward tailored cancer treatments. This specific trial focuses on melanoma, one of the most aggressive forms of skin cancer. Approval by the FDA would allow the combined therapy to enter the commercial market.
What is confirmed
- Moderna and Merck completed phase 3 clinical trials for a personalized mRNA vaccine to prevent melanoma from returning or spreading.
- The vaccine is administered alongside the drug Keytruda.
- Moderna stock surged 177% on August 19, 2026.
- The trial success is the final milestone required for the companies to apply for FDA approval.
What to watch next
- The official submission of the application for FDA approval
- FDA decision on the vaccine's safety and efficacy for commercial use
confidence 100%Sources used for this update (7)
- jen.jiji.com — 16-year-old who had left home found lifeless in the Po river
- jen.jiji.com — SuperEnalotto, draw and winning numbers for today, August 29, 2026
- www.whalesbook.com — Moderna-Merck Cancer Vaccine Succeeds in Phase 3 Trial
- starherald.com — Iran: Southern Iran Hit by Fuel Shortage.
- jen.jiji.com — Falls from third-floor balcony, 16-year-old dies in Savona
- www.briefs.co — Fed Official Calls for Policy Shift as AI Reshapes Economy
- www.briefs.co — The Stark Difference Between Typical and Top-Tier Savings Rates
-
Moderna and Merck mRNA Cancer Vaccine Awaits FDA Approval After Phase 3 Success
Moderna and Merck have completed phase 3 clinical trials for a personalized mRNA vaccine designed to prevent melanoma from returning or spreading in high-risk patients. The treatment is administered alongside the drug Keytruda. This successful trial represents the final milestone required for the companies to apply for FDA approval. The development has already influenced the stock prices of five biotechnology firms involved in manufacturing. Recent reports continue to identify the personalized mRNA cancer vaccine as a significant medical breakthrough.
Why it matters
Melanoma is a high-risk cancer where recurrence and metastasis are primary concerns for patient survival. Combining mRNA technology with existing immunotherapy like Keytruda aims to create a targeted defense against returning tumors. FDA authorization would move this from a clinical trial setting to standard medical practice.
What is confirmed
- Moderna and Merck developed a personalized mRNA vaccine to stop melanoma from returning or spreading in high-risk patients.
- The vaccine is used in combination with the drug Keytruda.
- Phase 3 clinical trials for the treatment have successfully concluded.
- The successful completion of phase 3 trials is the final requirement before the companies can apply for FDA approval.
Still unconfirmed
- The vaccine breakthrough has impacted the stock prices of five biotechnology firms involved in manufacturing.
- The personalized mRNA cancer vaccine is considered a medical breakthrough.
What to watch next
- Formal submission of the FDA approval application by Moderna and Merck
- FDA decision on the authorization of the vaccine for clinical use
confidence 90%Sources used for this update (9)
- jen.jiji.com — Accident with a holy water font in church, 6-year-old girl undergoes emergency aorta surgery in Bari
- san.com — A cancer vaccine breakthrough, medical AI faces a reality check and recalls pile up
- jen.jiji.com — Atalanta beats Hapoel 1-0 and qualifies for the Conference League
- jen.jiji.com — Heat, how to face tropical nights: the four (fundamental) tips from the expert
- jen.jiji.com — Ranucci, Esperia: "In the book he says Gabanelli called him while he was saving a man, but a video with another version emerges"
- jen.jiji.com — Norway, Mette-Marit is the new queen: a life between scandals and illnesses
- jen.jiji.com — Ukraine, still no aid package for Copasir: expected by September
- jen.jiji.com — F1: S.Pellegrino, Italian Grand Prix also takes place at the table (2)
- www.briefs.co — Japan's Unprecedented $96 Billion Move to Defend the Yen
-
Moderna and Merck personalized vaccine clears phase 3 trials for melanoma
Moderna and Merck have developed a personalized mRNA vaccine that prevents melanoma from returning or spreading in high-risk patients. The treatment is used in combination with the drug Keytruda and has successfully completed phase 3 clinical trials. This milestone is the final requirement before the companies can apply for FDA approval. The breakthrough has already impacted the stock prices of five biotechnology firms involved in the manufacturing process.
Why it matters
The vaccine is tailored to the specific tumors of individual patients. Development took a decade to overcome pandemic obstacles and logistical challenges. It represents a shift toward personalized cancer immunotherapy.
What is confirmed
- The personalized vaccine is used in combination with the drug Keytruda.
- The treatment has successfully completed phase 3 clinical trials.
- The vaccine targets melanoma in people at high risk of recurrence.
- Moderna and Merck developed the treatment over a ten year period.
Still unconfirmed
- Research funding cuts may threaten the future of the vaccine.
What to watch next
- FDA approval decision for market entry
- Clinical data on long-term recurrence rates
- Manufacturing agreements with the five identified biotech firms
confidence 95%Sources used for this update (6)
- jen.jiji.com — Lecce, head-on collision between two cars on provincial road 17: husband and wife dead
- jen.jiji.com — Juventus, Yildiz undergoes surgery? All options to replace him
- finance.yahoo.com — Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
- www.bbc.com — Will the new cancer vaccine survive RFK Jr’s America?
- www.sciencenews.org — A new cancer vaccine may keep melanoma from coming back
- www.geopop.it — Merck e Moderna annunciano il primo vaccino antitumorale a mRNA che supera la fase 3: come funziona
-
Moderna and Merck vaccine prevents melanoma recurrence in high-risk patients
Moderna and Merck announced Wednesday that an experimental personalized vaccine kept melanoma from returning or spreading in people at high risk of recurrence. The drugmakers spent a decade developing the treatment, overcoming logistical hurdles and pandemic-era obstacles. The vaccine is tailored to individual tumors and has completed phase 3 clinical trials. This successful trial is the final requirement before the companies can seek approval from the FDA to bring the treatment to market.
Why it matters
Melanoma is a dangerous form of skin cancer with a high risk of recurrence. Personalized mRNA technology allows for treatments specifically designed for a patient's unique tumor profile. Approval would mark a shift toward individualized cancer immunotherapy.
What is confirmed
- Moderna and Merck developed an experimental vaccine that prevented melanoma from returning or spreading in high-risk patients.
- The vaccine development process lasted a decade and faced pandemic-era obstacles and logistical challenges.
What to watch next
- FDA approval decision for the vaccine
- Results from long-term patient follow-up studies
confidence 100%Sources used for this update (5)
- jen.jiji.com — Trump, doctors warn: "His weight a significant health risk"
- medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
- jen.jiji.com — Vuelta a España, today third stage: schedule, route and where to watch it
- jen.jiji.com — USA, fire threatens Reno in Nevada, evacuation warnings for nearly 90,000 people
- www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
-
Vaccine breakthrough stops cancer returning in trial
A personalized mRNA vaccine developed by Moderna and Merck has shown promising results in preventing skin cancer from recurring in patients. The vaccine, which is tailored to individual tumors, successfully completed phase 3 clinical trials for treating melanoma. This milestone is the final step required before the drugmakers can seek approval from the FDA.
Why it matters
The treatment aims to stop skin cancer from returning or spreading. Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma. The vaccine's success in clinical trials is a significant breakthrough in the fight against cancer. Melanoma is a type of skin cancer that can be deadly if not treated promptly.
What is confirmed
- Moderna and Merck's personalized mRNA vaccine helped prevent the return and spread of melanoma in a trial involving more than 1,000 patients.
- The vaccine is tailored to individual tumors.
- The treatment aims to stop skin cancer from returning or spreading.
- Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma.
What to watch next
- FDA approval process for the vaccine
- Potential application of the vaccine to other types of cancer
- Long-term effects of the vaccine on patients
confidence 90%Sources used for this update (5)
- baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
- jen.jiji.com — 'Viva Mogol!' rerun wins TV ratings, Mediterranean Games opening on the podium
- www.livemint.com — It now seems possible to vaccinate against cancer
- jen.jiji.com — Sea Watch fined by Italy, NGO attacks government: "We don't collaborate with criminals, do you?"
- bismarcktribune.com — Moderna, Merck breakthrough could usher in cancer vaccines
-
Moderna and Merck cancer vaccine clears phase 3 melanoma trials
A personalized mRNA vaccine developed by Moderna and Merck successfully completed phase 3 clinical trials for treating melanoma. The treatment aims to stop skin cancer from returning or spreading by tailoring the vaccine to individual tumors. This milestone is the final step required before the drugmakers can seek approval from the FDA. Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma.
Why it matters
The vaccine adapts mRNA technology previously used in Covid-19 vaccines for oncology. Moderna and Merck shares hit 52-week highs following the announcement. The treatment represents a shift toward individualized cancer therapy.
What is confirmed
- The personalized mRNA vaccine succeeded in a final-stage melanoma trial.
- The treatment targets the recurrence and spread of skin cancer.
- Moderna and Merck developed the vaccine.
Still unconfirmed
- The vaccine could be used against other types of cancer.
- The vaccine is the last step necessary before FDA approval.
What to watch next
- FDA approval decision
- Clinical trial results for other cancer types
confidence 90%Sources used for this update (4)
- www.channelnewsasia.com — CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine
- consent.yahoo.com — Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial
- www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
- www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
-
Moderna and Merck mRNA vaccine reduces skin cancer recurrence in trial
A late-stage trial of an mRNA vaccine developed by Moderna and Merck shows promise in stopping cancer from returning. The treatment specifically targets the recurrence and spread of skin cancer. Following the announcement, Moderna and Merck shares reached 52-week highs, with Moderna stock seeing significant gains. This development marks a shift for Moderna as it applies its mRNA technology from Covid-19 vaccines to oncology.
Why it matters
mRNA technology allows for the creation of vaccines tailored to specific proteins. Reducing cancer recurrence is a critical goal in oncology to prevent late-stage metastasis. This trial tests whether the vaccine can prevent skin cancer from returning after initial treatment.
What is confirmed
- Moderna and Merck developed an mRNA vaccine that shows promise in a late-stage trial.
- The vaccine is designed to reduce the recurrence and spread of skin cancer.
- Moderna and Merck stocks reached 52-week highs following the trial results.
Still unconfirmed
- Moderna stock jumped 177% in a day.
- Moderna stock soared 90%.
What to watch next
- Publication of full peer-reviewed trial data
- FDA regulatory filing for the vaccine
- Results from expanded patient cohorts
confidence 90%Sources used for this update (5)
- CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
- NPR — New mRNA vaccine could reduce the recurrence and spread of skin cancer
- Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
- BBC — Vaccine breakthrough stops cancer returning in trial
- The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community